FA Clinical Outcome Measures

Active, not recruiting

• Conditions: Friedreich Ataxia; Neuro-Degenerative Disease

• Registration Number: NCT03090789
• Lead Sponsor: Friedreich's Ataxia Research Alliance

Brief Summary

This multicenter natural history study aims to expand the network of clinical research centers in FA, and to provide a framework for facilitating therapeutic interventions. In addition, this study will lead to the development of valid yet sensitive clinical measures crucial to outcome assessment of patients with Friedreich's Ataxia. This study will support genetic modifier studies, biomarker studies, and frataxin protein level assessments by building a sample repository.

This natural history study is no longer recruiting under this protocol NCT03090789 but remains actively recruiting under the harmonized study (UNIFAI) NCT06016946.

Detailed Description

Friedreich's ataxia (FA) is a rare autosomal recessive degenerative disorder characterized by ataxia, dysarthria, sensory loss, diabetes and cardiomyopathy. The discovery of the abnormal gene in FA and its product (frataxin) has provided insight into possible pathophysiological mechanisms and novel approaches to treatments in this disease. While such methods for assessing disease progression may be useful, evaluation in clinical trials will require specific clinical outcome measures.

This is a multicenter natural history study which aims to expand the network of clinical research centers specializing in Friedreich's Ataxia and to advance clinical care, research and therapeutic approaches in FA through the development and validation of clinical outcome measures. Study sites aim to collect quantitative serial clinical data on patients with FA and expand the existing research network. In addition, the study will support various genetic modifier studies, biomarker studies, and frataxin protein level assessments in patients with FA, in carriers, and in controls.

This study will recruit up to 2000 patients with Friedreich ataxia worldwide, to be assessed annually for up to 15 years. All individuals with a genetic or clinical diagnosis of FA can participate.

Study participation involves yearly assessments of a core set of clinical measures and quality of life assessment measures in addition to optional collection of a cheek swab and/or blood sample.

Study Timeline

• Study Start: 2001-01-01
• Study First Submitted: 2017-03-10
• Study First Submitted QC: 2017-03-21
• Study First Posted: 2017-03-27
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-02
• Last Update Posted: 2024-10-04
• Primary Completion: 2030-01-01
• Study Completion: 2030-01-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

1. Males or females age 4 to 80 years.
2. Genetically confirmed diagnosis of FA (for carrier/control cheek swab and blood samples this is not required).
3. Clinically confirmed diagnosis of FA, pending confirmatory genetic testing through a commercial or research laboratory (for carrier/control cheek swab and blood samples this is not required).
4. Parental/guardian permission (informed consent) and if appropriate, child assent.

Exclusion Criteria

1. Signs or symptoms of severe cardiomyopathy (such as congestive heart failure)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Friedreich Ataxia Rating Scale	once every 1 year	rating scale based on clinical neurologic examination

Secondary Outcome Measures

Name	Time	Method
9-hole peg test	once every 1 year	timed test of fine motor skills performed as a set of four trials (two trials per hand), for patients with FA who are able to complete this testing
timed 25 foot walk	once every 1 year	timed 25 foot walk is performed twice for patients with FA who are able to complete this testing. Assistive devices such as canes, service dogs, walkers, or crutches are permitted.
Vision assessment	once every 1 year	High and low contrast visual acuity tested on patients with FA who are able to perform this test. Glasses or contact lenses are permitted.
Quality of Life Questionnaires	once every 1 year	a set of quality of life questionnaires is administered for study participants with Friedreich ataxia. Questionnaires include items such as activities of daily living, overall opinion on health and function, and fatigue-related questions.

Trial Locations

Locations (14)

UCLA Ataxia Center; 🇺🇸 Los Angeles, California, United States

University of Colorado; 🇺🇸 Denver, Colorado, United States

University of Florida - Neurology; 🇺🇸 Gainesville, Florida, United States

USF Ataxia Research Center; 🇺🇸 Tampa, Florida, United States

Emory University Hospital - Neurology; 🇺🇸 Atlanta, Georgia, United States

University of Iowa, Stead Family Children's Hospital; 🇺🇸 Iowa City, Iowa, United States

Ohio State University - Neurology; 🇺🇸 Columbus, Ohio, United States

Children's Hospital of Philadelphia - Neurology; 🇺🇸 Philadelphia, Pennsylvania, United States

St. Jude Children's Research Hospital; 🇺🇸 Memphis, Tennessee, United States

Murdoch Childrens Research Institute; 🇦🇺 Parkville, Victoria, Australia

The Hospital for Sick Children; 🇨🇦 Toronto, Ontario, Canada

CHUM - Hopital Notre-Dame; 🇨🇦 Montréal, Quebec, Canada

All India Institute of Medical Sciences (Aiims); 🇮🇳 New Delhi, India

Auckland City Hospital; 🇳🇿 Auckland, New Zealand